Emcure Pharmaceuticals Limited Share Price & Analysis
₹1,924.5▲ +3.40%Updated 21 Jul 2026, 05:01 pm IST
LTP
₹1,924.5
+3.4%
Open
₹—
High
₹1,940
Low
₹1,874
Close
₹1,924.5
52W High
₹1,944
52W Low
₹1,260
Volume
215K
Lot Size
1
Sector
Healthcare
Market Cap
₹34K Cr
Face Value
₹10
Large CapNIFTY 500
Price Chart
Fundamentals
P/E
35.8
Sector P/E
54.4
P/B
7.37
EPS
₹45.89
ROE
20.1%
ROCE
24%
D/E Ratio
0.31
Div Yield
0.17%
Book Value
₹261
+
Strengths
- ✓Excellent return on equity (ROE 20.1%)
- ✓Efficient capital deployment (ROCE 24%)
- ✓Attractively valued vs sector (P/E 35.8x vs industry 54.4x)
- ✓Low debt relative to equity (D/E 0.3x)
−
Concerns
- ✗Trading near 52-week high (₹1,944)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
EMCURE · as of Mar 2026
Promoters77.87%
FII3.35%▼0.24
DII6.10%
Public12.69%▲0.26
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 77.94% | 77.92% | 77.92% | 77.88% | 77.87% | 77.87% |
| FII | 3.05% | 3.06% | 2.86% | 3.29% | 3.59% | 3.35% |
| DII | 3.87% | 3.44% | 2.84% | 4.36% | 6.10% | 6.10% |
| Public | 15.15% | 15.58% | 16.39% | 14.46% | 12.43% | 12.69% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Results5 Aug 2026
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend4 May 2026
Dividend - Rs 3 Per Share
Dividend13 Aug 2025
Latest News
All news →Emcure Pharma to acquire US-based pharmaceutical firm
*Emcure Pharma to acquire US-based pharmaceutical firm* in a strategic move to expand its global footprint. The deal value exceeds **₹500 crore**, marking a significant overseas foray. This acquisition is expected to enhance Emcure’s presence in the competitive US generics market. The move underscores aggressive growth via international consolidation. 📊 *STOCKS:* EMCUREPHARM | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Acquisition
NSE Filing3 Jul
Emcure Pharmaceuticals shares may react to investor presentation
*Emcure Pharmaceuticals shares may react to investor presentation*. Company released an investor presentation with operational and financial updates. No major announcements were made, suggesting minimal immediate impact. Traders may assess guidance and R&D pipeline for sentiment. 📊 *STOCKS:* EMCURE | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorPresentation
NSE Filing12 Jun
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.4K Cr ▲4.1% | ₹2.3K Cr ▲8.0% | ₹2.1K Cr ▼0.7% | ₹2.1K Cr ▲7.8% | ₹2.0K Cr ▼1.9% | ₹2.0K Cr ▲10.3% | ₹1.8K Cr ▲2.5% | ₹1.8K Cr |
| Op. Profit | ₹493 Cr ▲3.8% | ₹475 Cr ▲13.9% | ₹417 Cr ▲3.7% | ₹402 Cr ▲13.2% | ₹355 Cr ▼6.8% | ₹381 Cr ▲13.4% | ₹336 Cr ▲8.0% | ₹311 Cr |
| OPM | 21.0% ▲0.0% | 21.0% ▲5.0% | 20.0% ▲5.3% | 19.0% ▲5.6% | 18.0% ▼5.3% | 19.0% ▲0.0% | 19.0% ▲5.6% | 18.0% |
| Net Profit | ₹231 Cr ▼8.0% | ₹251 Cr ▲16.7% | ₹215 Cr ▲9.1% | ₹197 Cr ▲26.3% | ₹156 Cr ▼22.8% | ₹202 Cr ▲32.0% | ₹153 Cr ▲26.4% | ₹121 Cr |
| EPS (₹) | 12.16 ▼5.3% | 12.84 ▲17.6% | 10.92 ▲9.5% | 9.97 ▲22.9% | 8.11 ▼21.2% | 10.29 ▲29.4% | 7.95 ▲25.0% | 6.36 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹9.2K Cr ▲16.6% | ₹7.9K Cr ▲18.6% | ₹6.7K Cr ▲11.2% | ₹6.0K Cr ▲2.2% | ₹5.9K Cr ▲16.3% | ₹5.0K Cr ▼0.3% | ₹5.0K Cr ▲7.0% | ₹4.7K Cr |
| Expenses | ₹7.3K Cr ▲14.2% | ₹6.4K Cr ▲18.4% | ₹5.4K Cr ▲13.0% | ₹4.8K Cr ▲6.2% | ₹4.5K Cr ▲18.5% | ₹3.8K Cr ▼12.1% | ₹4.3K Cr ▲9.4% | ₹4.0K Cr |
| Op. Profit | ₹1.9K Cr ▲27.0% | ₹1.5K Cr ▲19.4% | ₹1.2K Cr ▲4.1% | ₹1.2K Cr ▼11.1% | ₹1.3K Cr ▲9.4% | ₹1.2K Cr ▲71.8% | ₹708 Cr ▼5.5% | ₹749 Cr |
| OPM | 20.0% ▲5.3% | 19.0% ▲5.6% | 18.0% ▼10.0% | 20.0% ▼13.0% | 23.0% ▼4.2% | 24.0% ▲71.4% | 14.0% ▼12.5% | 16.0% |
| Other Income | ₹-19 Cr ▼130.6% | ₹62 Cr ▲31.9% | ₹47 Cr ▲20.5% | ₹39 Cr ▼38.1% | ₹63 Cr ▲139.6% | ₹-159 Cr ▼536.0% | ₹-25 Cr ▼134.7% | ₹72 Cr |
| Interest | ₹144 Cr ▼18.2% | ₹176 Cr ▼25.7% | ₹237 Cr ▲10.7% | ₹214 Cr ▲21.6% | ₹176 Cr ▲13.5% | ₹155 Cr ▼39.7% | ₹257 Cr ▲15.2% | ₹223 Cr |
| Depreciation | ₹415 Cr ▲8.1% | ₹384 Cr ▲23.1% | ₹312 Cr ▲20.0% | ₹260 Cr ▲6.1% | ₹245 Cr ▼2.0% | ₹250 Cr ▼22.1% | ₹321 Cr ▲20.2% | ₹267 Cr |
| PBT | ₹1.3K Cr ▲32.5% | ₹971 Cr ▲33.6% | ₹727 Cr ▼2.7% | ₹747 Cr ▼23.2% | ₹973 Cr ▲49.2% | ₹652 Cr ▲521.0% | ₹105 Cr ▼68.3% | ₹331 Cr |
| Tax % | 27.0% ▲0.0% | 27.0% ▲0.0% | 27.0% ▲8.0% | 25.0% ▼10.7% | 28.0% ▼22.2% | 36.0% ▲800.0% | 4.0% ▼89.2% | 37.0% |
| Net Profit | ₹941 Cr ▲33.1% | ₹707 Cr ▲33.9% | ₹528 Cr ▼6.0% | ₹562 Cr ▼20.1% | ₹703 Cr ▲67.8% | ₹419 Cr ▲314.9% | ₹101 Cr ▼51.7% | ₹209 Cr |
| EPS (₹) | 48.76 ▲35.6% | 35.96 ▲30.8% | 27.5 ▼6.5% | 29.42 ▼19.7% | 36.62 ▲58.2% | 23.15 ▲401.1% | 4.62 ▼57.2% | 10.79 |
| Div Payout | 7.0% ▼12.5% | 8.0% ▲14.3% | 7.0% ▲0.0% | 7.0% ▼12.5% | 8.0% ▲100.0% | 4.0% ▼92.6% | 54.0% ▲68.8% | 32.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||
| Equity Capital | ₹190 Cr ▲0.0% | ₹190 Cr ▲0.5% | ₹189 Cr ▲4.4% | ₹181 Cr ▲0.0% | ₹181 Cr ▲0.0% | ₹181 Cr ▲0.0% | ₹181 Cr ▲0.0% | ₹181 Cr ▲0.0% | ₹181 Cr |
| Reserves | ₹4.8K Cr ▲4.5% | ₹4.6K Cr ▲7.0% | ₹4.3K Cr ▲53.6% | ₹2.8K Cr ▲19.4% | ₹2.3K Cr ▲28.4% | ₹1.8K Cr ▼13.6% | ₹2.1K Cr ▲20.9% | ₹1.7K Cr ▲4.7% | ₹1.7K Cr |
| Borrowings | ₹1.6K Cr ▼6.1% | ₹1.7K Cr ▲62.2% | ₹1.0K Cr ▼56.2% | ₹2.3K Cr ▲0.0% | ₹2.3K Cr ▲5.3% | ₹2.2K Cr ▼4.0% | ₹2.3K Cr ▼0.7% | ₹2.3K Cr ▲9.4% | ₹2.1K Cr |
| Other Liabilities | ₹3.1K Cr ▲3.8% | ₹3.0K Cr ▲12.7% | ₹2.7K Cr ▲9.5% | ₹2.4K Cr ▲34.7% | ₹1.8K Cr ▼1.0% | ₹1.8K Cr ▼16.8% | ₹2.2K Cr ▲26.9% | ₹1.7K Cr ▲6.7% | ₹1.6K Cr |
| Total Liabilities | ₹9.6K Cr ▲2.3% | ₹9.4K Cr ▲15.6% | ₹8.1K Cr ▲5.4% | ₹7.7K Cr ▲16.2% | ₹6.6K Cr ▲10.2% | ₹6.0K Cr ▼11.0% | ₹6.8K Cr ▲13.6% | ₹6.0K Cr ▲6.9% | ₹5.6K Cr |
| Assets | |||||||||
| Fixed Assets | ₹3.4K Cr ▲3.4% | ₹3.3K Cr ▲3.5% | ₹3.2K Cr ▲2.3% | ₹3.1K Cr ▲45.6% | ₹2.1K Cr ▲5.0% | ₹2.0K Cr ▼6.6% | ₹2.2K Cr ▼8.1% | ₹2.4K Cr ▲6.0% | ₹2.2K Cr |
| CWIP | ₹172 Cr ▲19.4% | ₹144 Cr ▼18.6% | ₹177 Cr ▲11.3% | ₹159 Cr ▼61.3% | ₹411 Cr ▲28.4% | ₹320 Cr ▲6.0% | ₹302 Cr ▼37.7% | ₹485 Cr ▼16.5% | ₹581 Cr |
| Investments | ₹20 Cr ▼52.4% | ₹42 Cr ▼55.8% | ₹95 Cr ▼70.1% | ₹318 Cr ▲1172.0% | ₹25 Cr ▲0.0% | ₹25 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other Assets | ₹6.0K Cr ▲1.7% | ₹5.9K Cr ▲26.8% | ₹4.7K Cr ▲13.2% | ₹4.1K Cr ▲1.4% | ₹4.0K Cr ▲11.5% | ₹3.6K Cr ▼15.1% | ₹4.3K Cr ▲38.3% | ₹3.1K Cr ▲12.5% | ₹2.7K Cr |
| Total Assets | ₹9.6K Cr ▲2.3% | ₹9.4K Cr ▲15.6% | ₹8.1K Cr ▲5.4% | ₹7.7K Cr ▲16.2% | ₹6.6K Cr ▲10.2% | ₹6.0K Cr ▼11.0% | ₹6.8K Cr ▲13.6% | ₹6.0K Cr ▲6.9% | ₹5.6K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹944 Cr ▲10.8% | ₹852 Cr ▼22.3% | ₹1.1K Cr ▲46.9% | ₹747 Cr ▼2.7% | ₹768 Cr ▲9.1% | ₹704 Cr ▲40.8% | ₹500 Cr ▲12.6% | ₹444 Cr |
| Investing CF | ₹-1.2K Cr ▼1142.7% | ₹-96 Cr ▲86.6% | ₹-715 Cr ▼52.8% | ₹-468 Cr ▲18.5% | ₹-574 Cr ▼124.2% | ₹-256 Cr ▼52.4% | ₹-168 Cr ▲58.9% | ₹-409 Cr |
| Financing CF | ₹343 Cr ▲142.1% | ₹-814 Cr ▼396.3% | ₹-164 Cr ▼13.1% | ₹-145 Cr ▲4.6% | ₹-152 Cr ▲19.6% | ₹-189 Cr ▲37.2% | ₹-301 Cr ▲59.0% | ₹-735 Cr |
| Net Cash Flow | ₹94 Cr ▲262.1% | ₹-58 Cr ▼126.5% | ₹219 Cr ▲63.4% | ₹134 Cr ▲219.0% | ₹42 Cr ▼83.8% | ₹259 Cr ▲709.4% | ₹32 Cr ▲104.6% | ₹-700 Cr |
| Free Cash Flow | ₹400 Cr ▼15.8% | ₹475 Cr ▼40.7% | ₹801 Cr ▲132.2% | ₹345 Cr ▼1.1% | ₹349 Cr ▼38.9% | ₹571 Cr ▲57.7% | ₹362 Cr ▲828.2% | ₹39 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102d ▲9.7% | 93d ▼8.8% | 102d ▲1.0% | 101d ▲23.2% | 82d ▼23.4% | 107d ▲28.9% | 83d ▲10.7% | 75d |
| Inventory Days | 237d ▲5.8% | 224d ▼0.4% | 225d ▲0.9% | 223d ▼5.9% | 237d ▼19.1% | 293d ▲38.9% | 211d ▼9.8% | 234d |
| Days Payable | 175d ▲1.7% | 172d ▼10.9% | 193d ▲10.3% | 175d ▼4.9% | 184d ▼2.1% | 188d ▲41.4% | 133d ▼6.3% | 142d |
| Cash Conv. Cycle | 163d ▲12.4% | 145d ▲8.2% | 134d ▼9.5% | 148d ▲9.6% | 135d ▼36.3% | 212d ▲31.7% | 161d ▼3.6% | 167d |
| Working Capital Days | 62d ▼18.4% | 76d ▲171.4% | 28d ▲27.3% | 22d ▲144.4% | 9d ▲156.3% | -16d ▲42.9% | -28d ▼86.7% | -15d |
| ROCE | 24.0% ▲14.3% | 21.0% ▲10.5% | 19.0% ▼9.5% | 21.0% ▼19.2% | 26.0% ▲18.2% | 22.0% ▲100.0% | 11.0% | — |
Source: Screener.in · Lower days = better efficiency
About Emcure Pharmaceuticals Limited
Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally[1]
Healthcare · Pharmaceuticals & Biotechnology
Related Analysis
Frequently Asked Questions
What is Emcure Pharmaceuticals Limited share price today?▾
Emcure Pharmaceuticals Limited (EMCURE) is currently trading at ₹1,924.5 on NSE, up 3.40% as of the last market session. Prices update daily after market close on MarketNetra.
Is Emcure Pharmaceuticals Limited available in F&O (Futures & Options)?▾
Yes, Emcure Pharmaceuticals Limited (EMCURE) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Emcure Pharmaceuticals Limited 52-week high and low?▾
Emcure Pharmaceuticals Limited's 52-week high is ₹1,944 and the 52-week low is ₹1,260. The current price of ₹1,924.5 is 1.0% below the 52W high.
What is Emcure Pharmaceuticals Limited P/E ratio?▾
Emcure Pharmaceuticals Limited's current P/E ratio is 35.8. This indicates the market is paying ₹35.8 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Emcure Pharmaceuticals Limited options?▾
Emcure Pharmaceuticals Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade EMCURE options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.